Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease

DMM Disease Models and Mechanisms

Volumn 7, Issue 6, 2014, Pages 613-623

  Belmont, Peter J ^a   Budinska, Eva ^b,c   Jiang, Ping ^a   Sinnamon, Mark J ^d   Coffee, Erin ^d   Roper, Jatin ^d   Xie, Tao ^a   Rejto, Paul A ^a   Derkits, Sahra ^e   Sansom, Owen J ^e   Delorenzi, Mauro ^c   Tejpar, Sabine ^f   Hung, Kenneth E ^g   Martin, Eric S ^a  

^a PFIZER INC   (United States)

^b MASARYK UNIVERSITY   (Czech Republic)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^d TUFTS MEDICAL CENTER   (United States)

^e BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g Pfizer BioTherapeutics Research   (United States)

Author keywords

BRAF; Colorectal cancer; GEMM; Genomic signatures; KRAS; MAPK

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; SELUMETINIB; B RAF KINASE; BRAF PROTEIN, HUMAN;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL VIABILITY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENETICALLY ENGINEERED MOUSE STRAIN; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNAL VALIDITY; MOUSE; MOUSE MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SPECIES; UPREGULATION; ANIMAL; COLORECTAL TUMOR; DISEASE MODEL; ENZYMOLOGY; GENETICS; METABOLISM; ONCOGENE RAS; PATHOLOGY; SPECIES DIFFERENCE;

ALLELES; ANIMALS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; GENES, RAS; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS B-RAF; SPECIES SPECIFICITY;

EID: 84902241934     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.013904     Document Type: Article

References (42)

1. Arnold, C. N., Goel, A., Blum, H. E. and Boland, C. R. (2005). Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer 104, 2035-2047. (Pubitemid 41579948)
2. Betensky, R. A., Louis, D. N. and Cairncross, J. G. (2002). Influence of unrecognized molecular heterogeneity on randomized clinical trials. J. Clin. Oncol. 20, 2495-2499. (Pubitemid 34525735)
3. Budinska, E., Popovici, V., Tejpar, S., D'Ario, G., Lapique, N., Sikora, K. O., Di Narzo, A. F., Yan, P., Hodgson, J. G., Weinrich, S. et al. (2013). Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J. Pathol. 231, 63-76.
4. Cancer Genome Atlas Network (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337.
5. Clevers, H. (2006). Wnt/beta-catenin signaling in development and disease. Cell 127, 469-480.
6. Coffee, E. M., Faber, A. C., Roper, J., Sinnamon, M. J., Goel, G., Keung, L., Wang, W. V., Vecchione, L., de Vriendt, V., Weinstein, B. J. et al. (2013). Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin. Cancer Res. 19, 2688-2698.
7. de Bono, J. S. and Ashworth, A. (2010). Translating cancer research into targeted therapeutics. Nature 467, 543-549.
8. De Sousa E Melo, F., Wang, X., Jansen, M., Fessler, E., Trinh, A., de Rooij, L. P., de Jong, J. H., de Boer, O. J., van Leersum, R., Bijlsma, M. F. et al. (2013). Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 19, 614-618.
9. Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M. et al. (2010). Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 70, 2264-2273.
10. DuPage, M., Dooley, A. L. and Jacks, T. (2009). Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064-1072.
11. Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y. et al. (2008). Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356.
12. Frese, K. K. and Tuveson, D. A. (2007). Maximizing mouse cancer models. Nat. Rev. Cancer 7, 654-658.
13. Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J. et al. (2012). Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575.
14. Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C. et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158. (Pubitemid 46398669)
15. Hegde, G. V., de la Cruz, C. C., Chiu, C., Alag, N., Schaefer, G., Crocker, L., Ross, S., Goldenberg, D., Merchant, M., Tien, J. et al. (2013). Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci. Transl. Med. 5, 171ra118.
16. Heyer, J., Kwong, L. N., Lowe, S. W. and Chin, L. (2010). Non-germline genetically engineered mouse models for translational cancer research. Nat. Rev. Cancer 10, 470-480.
17. Hung, K. E., Maricevich, M. A., Richard, L. G., Chen, W. Y., Richardson, M. P., Kunin, A., Bronson, R. T., Mahmood, U. and Kucherlapati, R. (2010). Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc. Natl. Acad. Sci. USA 107, 1565-1570.
18. Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A. and Jacks, T. (2001). Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111-1116. (Pubitemid 32391044)
19. Jonkers, J. and Berns, A. (2002). Conditional mouse models of sporadic cancer. Nat. Rev. Cancer 2, 251-265. (Pubitemid 37328779)
20. Jorissen, R. N., Gibbs, P., Christie, M., Prakash, S., Lipton, L., Desai, J., Kerr, D., Aaltonen, L. A., Arango, D., Kruhøffer, M. et al. (2009). Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clin. Cancer Res. 15, 7642-7651.
21. Kirk, R. (2011). Genetics: In colorectal cancer, not all KRAS mutations are created equal. Nat Rev Clin Oncol 8, 1.
22. Kirsch, D. G., Dinulescu, D. M., Miller, J. B., Grimm, J., Santiago, P. M., Young, N. P., Nielsen, G. P., Quade, B. J., Chaber, C. J., Schultz, C. P. et al. (2007). A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat. Med. 13, 992-997. (Pubitemid 47222037)
23. Kuraguchi, M., Wang, X. P., Bronson, R. T., Rothenberg, R., Ohene-Baah, N. Y., Lund, J. J., Kucherlapati, M., Maas, R. L. and Kucherlapati, R. (2006). Adenomatous polyposis coli (APC) is required for normal development of skin and thymus. PLoS Genet. 2, e146.
24. Lee, J. T. and Gu, W. (2010). The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 17, 86-92.
25. Levine, A. J. and Puzio-Kuter, A. M. (2010). The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340-1344.
26. Martin, E. S., Belmont, P. J., Sinnamon, M. J., Richard, L. G., Yuan, J., Coffee, E. M., Roper, J., Lee, L., Heidari, P., Lunt, S. Y. et al. (2013). Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin. Cancer Res. 19, 2929-2940.
27. Politi, K. and Pao, W. (2011). How genetically engineered mouse tumor models provide insights into human cancers. J. Clin. Oncol. 29, 2273-2281.
28. Pollock, C. B., Shirasawa, S., Sasazuki, T., Kolch, W. and Dhillon, A. S. (2005). Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res. 65, 1244-1250. (Pubitemid 40270149)
29. Popovici, V., Budinská, E. and Delorenzi, M. (2011). Rgtsp: a generalized top scoring pairs package for class prediction. Bioinformatics 27, 1729-1730.
30. Popovici, V., Budinska, E., Tejpar, S., Weinrich, S., Estrella, H., Hodgson, G., Van Cutsem, E., Xie, T., Bosman, F. T., Roth, A. D. et al. (2012). Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J. Clin. Oncol. 30, 1288-1295.
31. Racker, E., Resnick, R. J. and Feldman, R. (1985). Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. Proc. Natl. Acad. Sci. USA 82, 3535-3538. (Pubitemid 15243881)
32. Rajalingam, K., Schreck, R., Rapp, U. R. and Albert, S. (2007). Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 1773, 1177-1195. (Pubitemid 47125979)
33. Roper, J. and Hung, K. E. (2012). Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development. Trends Pharmacol. Sci. 33, 449-455.
34. Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C. et al. (2010). Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. 28, 466-474.
35. Rudrapatna, V. A., Cagan, R. L. and Das, T. K. (2012). Drosophila cancer models. Dev. Dyn. 241, 107-118.
36. Sadanandam, A., Lyssiotis, C. A., Homicsko, K., Collisson, E. A., Gibb, W. J., Wullschleger, S., Ostos, L. C., Lannon, W. A., Grotzinger, C., Del Rio, M. et al. (2013). A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19, 619-625.
37. Sumimoto, H., Imabayashi, F., Iwata, T. and Kawakami, Y. (2006). The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203, 1651-1656. (Pubitemid 44036269)
38. Tuveson, D. and Hanahan, D. (2011). Translational medicine: Cancer lessons from mice to humans. Nature 471, 316-317.
39. Tuveson, D. A. and Jacks, T. (2002). Technologically advanced cancer modeling in mice. Curr. Opin. Genet. Dev. 12, 105-110. (Pubitemid 34094998)
40. Van Cutsem, E., Labianca, R., Bodoky, G., Barone, C., Aranda, E., Nordlinger, B., Topham, C., Tabernero, J., André, T., Sobrero, A. F. et al. (2009). Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27, 3117-3125.
41. Vidal, M. and Cagan, R. L. (2006). Drosophila models for cancer research. Curr. Opin. Genet. Dev. 16, 10-16. (Pubitemid 43089606)
42. Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J. K., Markowitz, S., Zhou, S. et al. (2009). Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325, 1555-1559.